Severe Pazopanib-Induced Hepatotoxicity: Clinical and Histologic Course in Two Patients
- 20 September 2012
- journal article
- case report
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 30 (27) , e264-e268
Abstract
No abstract availableThis publication has 11 references indexed in Scilit:
- Risk of high-grade liver toxicity with pazopanib in patients with cancer: A meta-analysis.Journal of Clinical Oncology, 2011
- Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III TrialJournal of Clinical Oncology, 2010
- Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell CarcinomaJournal of Clinical Oncology, 2009
- Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation TrialJournal of Clinical Oncology, 2009
- Cancer Statistics, 2007CA: A Cancer Journal for Clinicians, 2007
- Renal-Cell CarcinomaNew England Journal of Medicine, 2005
- Role ofVHLGene Mutation in Human CancerJournal of Clinical Oncology, 2004
- Drug-Induced HepatotoxicityNew England Journal of Medicine, 2003
- Biochemical and Cellular Mechanisms of Toxic Liver InjurySeminars in Liver Disease, 2002
- Survival and Prognostic Stratification of 670 Patients With Advanced Renal Cell CarcinomaJournal of Clinical Oncology, 1999